{"entity":{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","aka":[],"tldr":"Radiochemist who built the zirconium-89 immuno-PET platform and MSKCC's radiopharmaceutical pipeline.","summary":"Jason Lewis developed methods for labelling antibodies with zirconium-89 that made immuno-PET a clinical reality, including 89Zr-trastuzumab and 89Zr-J591 PSMA imaging, and leads a laboratory translating new radiotracers and radioligand therapies from chemistry to first-in-human trials. He directs radiochemistry at MSKCC and has trained many of the field's leaders.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lewis%20JS%5BAuthor%5D%20zirconium-89%20PET"}],"tags":["radiochemistry","immuno-pet","theranostics"],"related":[],"cancers":[],"sections":[],"technologies":["immuno-pet","her2-pet","radioligand-therapy"],"targets":["her2","psma"],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-nuclear-medicine"],"dependsOn":[],"notes":[],"role":"Emily Tow Jackson Chair in Oncology and Chief Attending, Radiochemistry and Imaging Sciences Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Radiochemistry","Immuno-PET","Radiopharmaceutical development","Targeted radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lewis%20JS%5BAuthor%5D%20zirconium-89%20PET"}],"papers":[{"title":"89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo","journal":"Journal of Nuclear Medicine","year":2010,"doi":"10.2967/jnumed.110.077982"},{"title":"Immuno-PET of HER2-positive breast cancer with 89Zr-trastuzumab: a first-in-human study","journal":"Journal of Nuclear Medicine","year":2016}]},"route":"/people/jason-lewis/","neighbours":{"technology":[{"id":"her2-pet","kind":"technology","name":"HER2 PET","route":"/technologies/her2-pet/"},{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"journal":[{"id":"journal-of-nuclear-medicine","kind":"journal","name":"Journal of Nuclear Medicine","route":"/journals/journal-of-nuclear-medicine/"}]}}